XNAS
RNAZ
Market cap7mUSD
Jul 22, Last price
9.44USD
1D
-2.58%
1Q
2,906.37%
IPO
-99.78%
Name
Transcode Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
94.64%
Rev. gr., 5y
%
Revenues
0k
Net income
-19m
L-47.21%
CFO
-18m
L+14.67%
Profile
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
IPO date
Apr 28, 2021
Employees
19
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 19,419 | 18,764 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (19,419) | (18,764) | ||||
NOPBT Margin | ||||||
Operating Taxes | 17,565 | |||||
Tax Rate | ||||||
NOPAT | (19,419) | (36,329) | ||||
Net income | (18,546) -47.21% | (35,130) 406.31% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 15,909 | 5,989 | ||||
BB yield | -1,348.24% | -68.57% | ||||
| Debt | ||||||
Debt current | 412 | |||||
Long-term debt | 489 | |||||
Deferred revenue | ||||||
Other long-term liabilities | 4,347 | |||||
Net debt | (1,866) | (4,968) | ||||
| Cash flow | ||||||
Cash from operating activities | (18,075) | (15,763) | ||||
CAPEX | (36) | (101) | ||||
Cash from investing activities | (36) | (101) | ||||
Cash from financing activities | 15,909 | 6 | ||||
FCF | (19,812) | (36,332) | ||||
| Balance | ||||||
Cash | 2,768 | 4,968 | ||||
Long term investments | ||||||
Excess cash | 2,768 | 4,968 | ||||
Stockholders' equity | (46,416) | (27,869) | ||||
Invested Capital | 48,508 | 31,110 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 179 | 16 | ||||
Price | 6.59 -98.78% | 538.40 -73.50% | ||||
Market cap | 1,180 -86.49% | 8,734 -59.19% | ||||
EV | (686) | 3,766 | ||||
EBITDA | (18,902) | (18,666) | ||||
EV/EBITDA | 0.04 | |||||
Interest | 51 | 17,565 | ||||
Interest/NOPBT | ||||||